Neoplasma. 2017;64(6):938-944. doi: 10.4149/neo_2017_618.
In non-small cell lung cancer (NSCLC) circulating tumor cells (CTCs) can provide information on patient prognosis and treatment efficacy. Currently CTCs are mostly isolated in vitro from small volumes of patient blood samples. The aim of the study was to assess a medical device for in vivo isolation of CTCs directly from the blood of NSCLC patients. The device was inserted in a cubital vein through a standard cannula for thirty minutes. The interaction of target CTCs with the CellCollector was mediated by an antibody directed against the epithelial cell adhesion molecule. There were 60 applications of the wire in 48 stage I-IIIB NSCLC patients and 12 non-cancer patients. The device was well tolerated in all applications without side effects. We obtained in vivo isolation of CTCs in 32 of 34 NSCLC patients (94.1%) with a median (range) of 13 (0-300) CTCs. In the non-cancer patients, no CTCs were detected. The safety and efficacy of an in vivo CTC detection method directly from the bloodstream of patients with NSCLC has been demonstrated. This proof of concept study may have important clinical implications, as the implementation of the device into clinical practice may improve early detection, prognosis and therapy monitoring of NSCLC patients.
在非小细胞肺癌 (NSCLC) 中，循环肿瘤细胞 (CTC) 可以提供有关患者预后和治疗效果的信息。目前，CTC 主要是从患者的小体积血液样本中在体外分离出来的。本研究旨在评估一种用于直接从 NSCLC 患者血液中分离 CTC 的医疗设备。该设备通过标准套管插入肘静脉中 30 分钟。靶 CTC 与 CellCollector 的相互作用是通过针对上皮细胞黏附分子的抗体介导的。在 48 例 I 期-IIIB 期 NSCLC 患者和 12 例非癌症患者中进行了 60 次应用。该设备在所有应用中均耐受良好，无副作用。我们在 34 例 NSCLC 患者中的 32 例（94.1%）中获得了体内 CTC 分离，中位数（范围）为 13（0-300）个 CTC。在非癌症患者中，未检测到 CTC。已经证明了一种从 NSCLC 患者血流中直接进行体内 CTC 检测的方法的安全性和有效性。这项概念验证研究可能具有重要的临床意义，因为该设备的临床应用可能会改善 NSCLC 患者的早期检测、预后和治疗监测。
